n South African Medical Journal - Issues in research : the SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis : forum
|Article Title||Issues in research : the SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis : forum|
|© Publisher:||Health and Medical Publishing Group (HMPG)|
|Journal||South African Medical Journal|
|Author||Quarraisha Abdool Karim, Salim S. Abdool Karim, Cheryl Baxter, Gerald Friedland, Tanuja Gengiah, Andrew Gray, Anneke Grobler, Kogieleum Naidoo, Nesri Padayatchi and Wafaa El-Sadr|
|Publication Date||Dec 2010|
|Pages||808 - 809|
|Keyword(s)||Centre for the AIDS Programme of Research in South Africa (CAPRISA), Columbia University, International Center for AIDS Care and Treatment Programs (ICAP), University of KZN and Yale University|
Boulle et al. queried whether a clinical trial was needed to provide the evidence for the mortality benefits of antiretroviral therapy (ART) initiation during tuberculosis (TB) treatment. While several experts, including foremost TB-HIV scientists from South Africa and the USA, senior World Health Organization (WHO) and UNAIDS officials at the time the study was initiated, the 2003 WHO AIDS Treatment Guidelines Committee Chair, the Chair of the Ethics Committee and the researchers, have previously addressed the points raised, the SAPIT (Starting Antiretroviral Therapy at Three Points in Tuberculosis) research team welcomes the opportunity also to address the comments. We hold Boulle and his colleagues in high regard and appreciate their contributions to the field of HIV and tuberculosis co-infection. More importantly, we share with them the common goal of rigorously and relentlessly seeking answers to critically important research questions as we confront the devastating dual AIDS and tuberculosis epidemics.
Article metrics loading...